MNKD MannKind Corporation
$3.29▲ +1.86%
Healthcare
Other
Pre-market
$3.21▼ -2.36%
Oct 28, 4:00 AM ET
Volume 2.50M
Avg Volume (10D) 3.26M
Key Metrics & Fundamentals
Market Cap
$1.06B
P/E Ratio
–
Div Yield
0.00%
52W Range
2.23 - 6.51
% vs 50 MA
-9.34%
% vs 200 MA
-12.56%
RSI-14
47.2
MACD Histogram
+0.0200
Beta (1Y vs SPY)
1.01
Free Cash Flow
-$23.45M
Gross Rev
$109.38M
Gross Profit
$79.84M
EBITDA
$1.98M
COGS
$29.54M
Operating Exp
$80.67M
Operating Income
-$835,000
EBIT
-$835,000
Pretax Income
-$19.14M
Net Income
-$19.03M
EPS (Diluted)
-0.06
Price & Volume History
Loading chart…
Recent News
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MarketBeat · Oct 20, 2026 4:03 PM ET
Learn Why The Bull Case For MannKind Stock Could Change Following Outpatient Diuretic Data
Simply Wall St. · Oct 19, 2026 11:12 PM ET
Chardan Initiates MannKind at Buy With $10 Price Target
MT Newswires · Oct 19, 2026 8:15 AM ET
Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation?
Simply Wall St. · Oct 15, 2026 8:21 PM ET
MannKind to Participate in the Chardan Healthcare Conference
GlobeNewswire · Oct 14, 2026 4:01 PM ET
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
GlobeNewswire · Oct 9, 2026 8:00 PM ET
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MarketBeat · Sep 17, 2026 6:02 PM ET
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
Insider Monkey · Sep 15, 2026 10:58 PM ET
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching
Stocktwits · Sep 9, 2026 8:36 AM ET
MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug
MT Newswires · Sep 9, 2026 7:08 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See MNKD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.